| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2792527 | Cell Metabolism | 2016 | 14 Pages |
•The FGF21 analog PF-05231023 reduced body weight in obese monkeys and humans•PF-05231023 improved the circulating lipid profile in monkeys and humans•PF-05231023 elevated adiponectin levels but did not improve glycemic control•Multiple markers of bone formation and resorption were modulated by PF-05231023
SummaryFGF21 plays a central role in energy, lipid, and glucose homeostasis. To characterize the pharmacologic effects of FGF21, we administered a long-acting FGF21 analog, PF-05231023, to obese cynomolgus monkeys. PF-05231023 caused a marked decrease in food intake that led to reduced body weight. To assess the effects of PF-05231023 in humans, we conducted a placebo-controlled, multiple ascending-dose study in overweight/obese subjects with type 2 diabetes. PF-05231023 treatment resulted in a significant decrease in body weight, improved plasma lipoprotein profile, and increased adiponectin levels. Importantly, there were no significant effects of PF-05231023 on glycemic control. PF-05231023 treatment led to dose-dependent changes in multiple markers of bone formation and resorption and elevated insulin-like growth factor 1. The favorable effects of PF-05231023 on body weight support further evaluation of this molecule for the treatment of obesity. Longer studies are needed to assess potential direct effects of FGF21 on bone in humans.
Graphical AbstractFigure optionsDownload full-size imageDownload high-quality image (181 K)Download as PowerPoint slide
